VoxNeuro is giving the brain a voice through cognitive health assessment

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

VoxNeuro’s software as a medical device (SaMD) is transforming cognitive health assessment as it pushes the boundaries of our understanding of the brain to improve decision-making by clinicians and patients.

“Our breakthrough SaMD technology uses validated brain biomarkers, not behavior, to compare a patient’s performance against a normative database. The output is objective, biological scores that are applicable to a range of neurology and psychiatry conditions that impact cognitive health,” Jason Flowerday, CEO of VoxNeuro, said in an interview with BioTuesdays.

“Our instantly-generated reports provide clinicians and patients with a comprehensive understanding of how a brain is functioning in attention and concentration, information processing and memory,” he added.

Read the entire interview in Bio Tuesdays to learn more about VoxNeuro’s work in brain health and the technology to comprehensively understand how a brain functions.

VoxNeuro is an OBIO® member.

Arsheen Kaur
Previous

TIAP and Evotec Expand LAB150 BRIDGE Partnership to Include Amgen
Next

Winterlight Labs announces data demonstrating the sensitivity of speech-based digital measures in detecting longitudinal change in Alzheimer’s disease in collaboration with Genentech